NCT05368207Completed
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1 (actual)
- First submitted
- 10 Dec 2021
- Start date
- 6 Dec 2021
- Primary completion date
- 16 Oct 2025
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Ovarian cancer
- NCT number
- NCT05368207
What you commit to
- Study type: Interventional
- Participants enrolled: 1
- From 6 Dec 2021 to the primary completion date, 16 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- N/A
Who the study is looking for
- Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.